IDEAYA Biosciences, Inc. (IDYA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 80M 160M 240M Q2 '21: 35.5M Q3 '21: 35.5M Q4 '21: 27.9M Q1 '22: 32.1M Q2 '22: 29.1M Q3 '22: 49.9M Q4 '22: 50.9M Q1 '23: 47.5M Q2 '23: 45.1M Q3 '23: 23.5M Q4 '23: 23.4M Q1 '24: 15.5M Q2 '24: 12M Q3 '24: 3.9M Q4 '24: 7M Q2 '26: 234.1M Q3 '21 Q1 '22 Q3 '22 Q1 '23 Q3 '23 Q1 '24 Q3 '24 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '18: -36.4M Q1 '19: -40.4M Q2 '19: -44.1M Q3 '19: -42.1M Q4 '19: -44.3M Q1 '20: -46.7M Q2 '20: -48M Q3 '20: -41.4M Q4 '20: -35.3M Q1 '21: -32M Q2 '21: -30.5M Q3 '21: -37.2M Q4 '21: -50.3M Q1 '22: -55.4M Q2 '22: -66.8M Q3 '22: -54.4M Q4 '22: -62.5M Q1 '23: -74.6M Q2 '23: -84.8M Q3 '23: -119M Q4 '23: -134.4M Q1 '24: -159.2M Q2 '24: -191.4M Q3 '24: -224.8M Q4 '24: -327M Q1 '25: -360.3M Q2 '25: -384.2M Q3 '25: -208.9M Q4 '25: -159.3M Q1 '26: -183.5M Q2 '26: -217M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '18: -34.3M Q1 '19: -38.2M Q2 '19: -41.8M Q3 '19: -39.8M Q4 '19: -42M Q1 '20: -44.4M Q2 '20: -46.2M Q3 '20: -40.1M Q4 '20: -34.5M Q1 '21: -31.5M Q2 '21: -30M Q3 '21: -36.7M Q4 '21: -49.8M Q1 '22: -54.8M Q2 '22: -65.9M Q3 '22: -52.7M Q4 '22: -58.7M Q1 '23: -68.3M Q2 '23: -74.2M Q3 '23: -103.2M Q4 '23: -113M Q1 '24: -128.9M Q2 '24: -153.7M Q3 '24: -178.1M Q4 '24: -274.5M Q1 '25: -307.1M Q2 '25: -331.8M Q3 '25: -160.7M Q4 '25: -113.7M Q1 '26: -140.1M Q2 '26: -175M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q2 '19: -36.2M Q3 '19: -38.1M Q4 '19: -39.3M Q1 '20: -39.1M Q2 '20: -42.4M Q3 '20: 58.4M Q4 '20: 55.5M Q1 '21: 51.3M Q2 '21: 52M Q3 '21: -50.7M Q4 '21: -55.8M Q1 '22: -61.7M Q2 '22: -68.8M Q3 '22: -80.5M Q4 '22: -87.2M Q1 '23: -95.4M Q2 '23: -108.8M Q3 '23: -114.8M Q4 '23: -115.2M Q1 '24: -131.2M Q2 '24: -130.6M Q3 '24: -149.7M Q4 '24: -247.6M Q1 '25: -264.1M Q2 '25: -293.7M Q3 '25: -102.3M Q4 '25: -71.1M Q1 '26: -85.9M Q2 '26: -111.7M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-300M -150M 0 150M 300M 450M Q2 '19: -38.6M Q3 '19: -39.5M Q4 '19: -40.7M Q2 '21: 50M Q3 '21: -52.9M Q4 '21: -58.4M Q1 '22: -63.7M Q2 '22: -72.2M Q3 '22: -84.5M Q4 '22: -90.6M Q1 '23: -98.5M Q2 '23: -110.9M Q3 '23: -116.4M Q4 '23: -117.6M Q1 '24: -134.8M Q2 '24: -134.4M Q3 '24: -153.3M Q4 '24: -251.4M Q1 '25: -268M Q2 '25: -297.3M Q3 '25: -105.4M Q4 '25: -73.5M Q1 '26: -87.9M Q2 '26: -113.9M Q4 '19 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '21: 32.9M Q3 '21: 37.8M Q1 '22: 38.6M Q2 '22: 38.7M Q3 '22: 41.1M Q1 '23: 48.4M Q2 '23: 56.3M Q3 '23: 60M Q1 '24: 75.1M Q2 '24: 78M Q3 '24: 86.2M Q1 '25: 88.4M Q2 '25: 88.5M Q3 '25: 89.7M Q1 '26: 88.7M Q2 '26: 92.1M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q4 '18: -35.55 Q1 '19: -37.33 Q2 '19: -31.16 Q3 '19: -18.64 Q4 '19: -11.06 Q1 '20: -2.96 Q2 '20: -2.25 Q3 '20: -1.88 Q4 '20: -1.49 Q1 '21: -1.18 Q2 '21: -0.92 Q3 '21: -1.06 Q4 '21: -1.41 Q1 '22: -1.49 Q2 '22: -1.73 Q3 '22: -1.38 Q4 '22: -1.43 Q1 '23: -1.56 Q2 '23: -1.49 Q3 '23: -1.99 Q4 '23: -1.97 Q1 '24: -2.01 Q2 '24: -2.19 Q3 '24: -2.33 Q4 '24: -3.36 Q1 '25: -3.65 Q2 '25: -3.85 Q3 '25: -1.92 Q4 '25: -1.28 Q1 '26: -1.57 Q2 '26: -1.91 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.